Investor directoryBoehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund is dedicated to advancing scientific innovation in therapeutics.
The facts
- Typical cheque
- €1M – €30M
- Headquarters
- Ingelheim am Rhein, Germany
- Founded
- 2010
Portfolio companies
More portfolio companies
Agomab Therapeutics (NAS: AGMB)NBE TherapeuticsHookipa Pharma (OTCM: HOOK)RigontecAelin TherapeuticsEvlaBioCellaïonArrePathProTgen (Drug Discovery)Optina DiagnosticsImCheck TherapeuticsAnagenesis BiotechnologiesAsgard TherapeuticseTheRNADelonix BioworksTopas TherapeuticsAcousia TherapeuticsAbalos TherapeuticsEpsilogenWellth (Healthcare Technology Systems)DiogenXPulseSight TherapeuticsRgenta TherapeuticsAmal Therapeutics
and 21 more
Questions founders ask
- How much does Boehringer Ingelheim Venture Fund typically invest?
- Boehringer Ingelheim Venture Fund states a typical cheque of €1M – €30M.
- Which stages does Boehringer Ingelheim Venture Fund invest in?
- Boehringer Ingelheim Venture Fund invests at Seed, Series A and Series B.
- Where is Boehringer Ingelheim Venture Fund based?
- Boehringer Ingelheim Venture Fund is headquartered in Ingelheim am Rhein, Germany.
Does Boehringer Ingelheim Venture Fund fit your round?
In 30 minutes you'll know which funds matter for your round.
Get a demoSearch investors like this in Claude — no account, no sign-in. Open in Claude
Are you Boehringer Ingelheim Venture Fund? Tell us what to correct and we will update it — or ask us to remove the entry.